Update on Screening Breast MRI in High-Risk Women

被引:8
作者
Boetes, C. [1 ]
机构
[1] Maastricht Univ Med Ctr, Dept Radiol, NL-6202 AZ Maastricht, Netherlands
关键词
Breast; Cancer; Screening; Increased risk; MRI; MUTATION CARRIERS; OVARIAN-CANCER; BRCA2; GENE; GERMLINE MUTATIONS; AMERICAN-SOCIETY; FAMILY-HISTORY; MAMMOGRAPHY; POPULATION; SUSCEPTIBILITY; SURVEILLANCE;
D O I
10.1016/j.ogc.2011.02.007
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Breast cancer is a major health problem in Europe and the United States. At the moment, 1 in 8 women in the Western European countries develops breast cancer during her lifetime, and approximately 30% of these women die of the disease. Although a nationwide screening program for breast cancer has shown a mortality reduction of approximately 1.2% annually in the Netherlands, mammography has a limited sensitivity especially in the dense breast, and cancers are missed at screening.(1,2) In women with an increased risk for breast cancer, mammographic results are even more disappointing because in many cases these women are young, and younger women have often more dense breasts than postmenopausal women. The first results regarding breast cancer screening with MRI were published by Tilanus-Linthorst and colleagues(3) in 2000. In this series, MRI detected, in 3% of the cases, a malignancy not seen on conventional imaging. After that publication, many studies were published showing the value of screening with MRI and mammography compared with screening with mammography alone in the group of women with an increased risk for breast cancer.
引用
收藏
页码:149 / +
页数:12
相关论文
共 45 条
  • [1] [Anonymous], 1997, LANCET, V349, P1505
  • [2] Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies
    Antoniou, A
    Pharoah, PDP
    Narod, S
    Risch, HA
    Eyfjord, JE
    Hopper, JL
    Loman, N
    Olsson, H
    Johannsson, O
    Borg, Å
    Pasini, B
    Radice, P
    Manoukian, S
    Eccles, DM
    Tang, N
    Olah, E
    Anton-Culver, H
    Warner, E
    Lubinski, J
    Gronwald, J
    Gorski, B
    Tulinius, H
    Thorlacius, S
    Eerola, H
    Nevanlinna, H
    Syrjäkoski, K
    Kallioniemi, OP
    Thompson, D
    Evans, C
    Peto, J
    Lalloo, F
    Evans, DG
    Easton, DF
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) : 1117 - 1130
  • [3] Premalignant and in situ breast disease: Biology and clinical implications
    Arpino, G
    Laucirica, R
    Elledge, RM
    [J]. ANNALS OF INTERNAL MEDICINE, 2005, 143 (06) : 446 - 457
  • [4] Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer
    Athma, P
    Rappaport, R
    Swift, M
    [J]. CANCER GENETICS AND CYTOGENETICS, 1996, 92 (02) : 130 - 134
  • [5] Brose MS, 2002, J NATL CANCER I, V94, P1365, DOI 10.1093/jnci/94.18.1365
  • [6] American Society of Clinical Oncology policy statement update: Genetic testing for cancer susceptibility
    Bruinooge, SS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) : 2397 - 2406
  • [7] CLAUS EB, 1994, CANCER, V73, P643, DOI 10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO
  • [8] 2-5
  • [9] Claus EB, 1996, CANCER, V77, P2318, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO
  • [10] 2-Z